BioCentury
ARTICLE | Emerging Company Profile

Walden: targeting podocytes as linchpin for kidney function

Backed by Arch and UCB, Walden to enter the clinic next year with a mAb and small molecule targeting podocytes for kidney diseases

October 29, 2021 2:03 AM GMT

Access This Article